NDA 220482 · Haisco
Cypsedo
Cipepofol · Intravenous
NovelCDER novel approval, May 29, 2026: To induce general anesthesia in adults undergoing surgery
Last checked: Nov 19, 2026Latest source record: May 29, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
May 29, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
4
2 Phase 3, 2 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. FDA's summary: To induce general anesthesia in adults undergoing surgery
Therapeutic areas: Pain and anesthesia
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- CYPSEDO · CIPEPOFOL 50MG/20ML (2.5MG/ML) · EMULSION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Cipepofol" as an intervention, any sponsor and status, largest first.
- HSK3486 (Cipepofol) Injectable Emulsion for Induction of General Anesthesia in Pediatric Subjects Undergoing Elective SurgeryPivotal-lookingNot yet recruiting
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07510945 · 400 participants (planned) · Start May 2026 · Primary completion May 2028
Drug: HSK3486; propofol · For: General Anesthetic
- A Multicenter, Open, Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Cipepofol Injection for General Anesthesia in Pediatric Patients Undergoing Elective SurgeryPivotal-lookingCompleted
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT06391931 · 190 participants · Start Apr 7, 2024 · Primary completion Nov 6, 2024
Drug: Cipepofol; Propofol · For: Anesthesia
Sites: Shanghai, China
Haisco-USA Pharmaceuticals, Inc.Industry
NCT06795204 · 48 participants · Start Apr 9, 2024 · Primary completion May 19, 2024
Drug: HSK3486; Moxifloxacin Hydrochloride and 1 more · For: Anesthesia; Adverse Effect; Cardiac Arrhythmia
Sites: Beijing, China
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT06740201 · 40 participants (planned) · Start Jan 6, 2025 · Primary completion Mar 30, 2025
Drug: Cipepofol · For: Anesthesia
Sites: Chengde, China; Shijiazhuang, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Hemodynamic Impact of Cipepofol vs Propofol During Anesthesia Induction in Patients With Severe Aortic Stenosis: A Randomized Clinical Trial.
Ni T, Zhou X, Wu S, et al. · JAMA Surg 2025 · Comparative Study, Randomized Controlled Trial
- Safety and efficacy of cipepofol for painless digestive endoscopy in older patients: a randomized, double-blind, non-inferiority trial.
Xu Q, Zhang J, Yan X, et al. · BMC Geriatr 2025 · Equivalence Trial, Research Support, Non-U.S. Gov't
- Ciprofol pharmacology and dosing in various populations.
Jiang T, Miao M, Huang J, et al. · Expert Opin Pharmacother 2025 · Systematic Review
- Respiratory-related safety profiles of ciprofol (cipepofol) for anesthesia/sedation in Chinese elderly patients undergoing gastroscopy: a multicenter, parallel controlled clinical trial (REST trial).
Zhang X, Zhu T, Chen G, et al. · J Clin Anesth 2025 · Randomized Controlled Trial, Multicenter Study
- Remimazolam Reduces the Cough Reflexes in Elderly Patients Undergoing Fiberoptic Bronchoscopy Under Remifentanil/Cipepofol-Based Anaesthesia: A Randomized Clinical Trial.
Wang X, Qin Y, Wei Y, et al. · Drug Des Devel Ther 2026 · Randomized Controlled Trial
- Estimation of ED50 and ED95 of Oliceridine Required to Suppress the Bronchoscopy Response in Patients Undergoing Fiberoptic Bronchoscopy Under Sedation with Cipepofol: An Up-and-Down Sequential Allocation Trial.
Wu D, Liao Y, Qin Y, et al. · Drug Des Devel Ther 2025 · Clinical Trial
Sponsor: Haisco
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.